Sanofi taps new startup ScionxBio for long-acting RNA

PartnershipPositive

AI Analysis

Summary

ScionxBio, recently spun out of Eleven Therapeutics, signed its first partnership with Sanofi to screen Sanofi's mRNA candidates using its platform for long-acting RNA. Deal terms were not disclosed in the available text.

Outcome Details

ScionxBio will screen Sanofi's mRNA candidates for long-acting RNA; financial terms not disclosed in the available text.

Importance:5/10

Sentiment:

0.30

partnershipmRNAlong-acting RNARNA platformstartupspin-out

Related Companies

$SNY

Read the original article

Published by Endpoints News on October 19, 2026 1:00 PM

Read Original